Granted Patent
B2
US 12,465,655 · App. 17/612,833 · Granted Nov 11, 2025
UBE3A genes and expression cassettes and their use
Inventors:
Benjamin David Philpot (Durham, NC); Steven James Gray (Southlake, TX); Charles Shyng (Apex, NC); Matthew Judson (Chapel Hill, NC)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention relates to polynucleotides comprising UBE3A open reading frame (ORF) sequences, vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of a UBE3A gene or aberrant activity of a UBE3A gene product in the subject, such as Angelman Syndrome.
Claims (18)
1 . A polynucleotide comprising a human UBE3A open reading frame, wherein the human UBE3A open reading frame encodes human UBE3A short isoform and long isoform, wherein the human UBE3A long isoform is human UBE3A long isoform 2 or human UBE3A long isoform 3,
wherein the polynucleotide comprises a first Kozak sequence comprising SEQ ID NO:6 operably linked to coding sequences for the long isoform and a second Kozak sequence comprising SEQ ID NO:8 operably linked to coding sequences for the short isoform; and
wherein the polynucleotide is devoid of a sequence encoding an exogenously added secretory signal.
2 . The polynucleotide of claim 1 , wherein the human UBE3A open reading frame comprises one or more nucleotide modifications to reduce expression of the long isoform as compared to expression of native ORF which lacks the one or more nucleotide modifications to reduce expression.
3 . The polynucleotide of claim 1 , wherein the human UBE3A open reading frame comprises one or more nucleotide modifications to enhance expression of the short isoform as compared to native ORF not comprising nucleotide modifications to enhance expression.
4 . The polynucleotide of claim 1 , wherein the human UBE3A open reading frame comprises one or more nucleotide modifications to encode expression of the short isoform at a ratio of about 1:1 to about 15:1, as compared to expression of the long isoform.
5 . The polynucleotide of claim 1 , wherein the human UBE3A open reading frame comprises the nucleotide sequence of SEQ ID NO:9, SEQ ID NO:26, or SEQ ID NO:27, or a nucleotide sequence having at least about 95% identity thereto.
6 . An expression cassette comprising the polynucleotide of claim 1 .
7 . The expression cassette of claim 6 , wherein the human UBE3A open reading frame is operably linked to a promoter, a polyadenylation signal, and/or at least one adeno-associated virus (AAV) inverted terminal repeat (ITR).
8 . The expression cassette of claim 6 , wherein the expression cassette is a single stranded AAV genome.
9 . The expression cassette of claim 6 , wherein the expression cassette comprises an AAV2 ITR, a human synapsin promoter, the human UBE3A open reading frame comprising human UBE3A short isoform and long isoform 2, a bGHpA, and an AAV2 ITR.
10 . The expression cassette of claim 6 , wherein the expression cassette comprises an AAV2 ITR, a human synapsin promoter, the human UBE3A open reading frame comprising human UBE3A short isoform and long isoform 3, a bGHpA, and an AAV2 ITR.
11 . The expression cassette of claim 9 , wherein the expression cassette comprises an AAV2 ITR; a human synapsin promoter; the human UBE3A open reading frame comprising human UBE3A short isoform and long isoform 2 further comprising one or more Kozak sequences comprising SEQ ID NO:6 and SEQ ID NO:8; a bGHpA; and an AAV2 ITR.
12 . The expression cassette of claim 10 , wherein the expression cassette comprises an AAV2 ITR; a human synapsin promoter; the human UBE3A open reading frame comprising human UBE3A short isoform and long isoform 3 further comprising one or more Kozak sequences comprising SEQ ID NO:6 and SEQ ID NO:8; a bGHpA; and an AAV2 ITR.
13 . The expression cassette of claim 12 , comprising the nucleotide sequence of SEQ ID NO:14 or a sequence at least about 90% identical thereto.
14 . A vector comprising the polynucleotide of claim 1 .
15 . The vector of claim 14 , wherein the vector is an AAV vector.
16 . A pharmaceutical composition comprising the polynucleotide of claim 1 in a pharmaceutically acceptable carrier.
Assignments (2)
RELEASE OF SECURITY INTEREST
Recorded Feb 13, 2026
From: TRINITY CAPITAL INC.
To: TAYSHA GENE THERAPIES, INC.
Reel/Frame 074858/0456 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 6, 2021
From: PHILPOT, BENJAMIN DAVID; GRAY, STEVEN JAMES; SHYNG, CHARLES; JUDSON, MATTHEW
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 058307/0629 →
Continuity (2)
Provisional Application
62851411
· May 22, 2019
References Cited (121)
US 4501729A
· Boucher et al.
· 1985
[cited by applicant]
US 5399346A
· Anderson et al.
· 1995
[cited by applicant]
US 5478745A
· Samulski et al.
· 1995
[cited by applicant]
US 6040183A
· Ferrari et al.
· 2000
[cited by applicant]
US 6093570A
· Ferrari et al.
· 2000
[cited by applicant]
US 6156303A
· Russell et al.
· 2000
[cited by applicant]
US 7201898B2
· Monahan et al.
· 2007
[cited by applicant]
US 9636370B2
· Mccown et al.
· 2017
[cited by applicant]
US 20160243260A1
· Blits
· 2016
[cited by examiner]
JP 2018518946A
· 2018
[cited by applicant]
WO 9811244A2
· 1998
[cited by applicant]
WO 9961601A2
· 1999
[cited by applicant]
WO 0017377A2
· 2000
[cited by applicant]
WO 0028004A1
· 2000
[cited by applicant]
WO 0028061A2
· 2000
[cited by applicant]
WO 0191803A2
· 2001
[cited by applicant]
WO 0192551A2
· 2001
[cited by applicant]
WO 2016179584A1
· 2016
[cited by applicant]
WO 2019006107A1
· 2019
[cited by applicant]
WO 2020191366A1
· 2020
[cited by applicant]
WO 2021035181A1
· 2021
[cited by applicant]
Yamamoto, Yoshiki, Jon M. Huibregtse, and Peter M. Howley. Genomics 41.2 (1997): 263-266. (Year: 1997).
[cited by examiner]
Buiting, Karin, Charles Williams, and Bernhard Horsthemke. Nature Reviews Neurology 12.10 (2016): 584-593. (Year: 2016).
[cited by examiner]
Sequence Search Results, 20241112_112934_us-17-612-833-26.align50.rnpbm, result 16 (Year: 2024).
[cited by examiner]
Sadhwani, Anjali, et al. American Journal of Medical Genetics Part A 176.7 (2018): 1641-1647. (Year: 2018).
[cited by examiner]
Ward, Natalie J., et al. Blood, The Journal of the American Society of Hematology 117.3 (2011): 798-807. (Year: 2011).
[cited by examiner]
Acevedo, Julieta M., et al. Scientific reports 8.1 (2018): 4018. (Year: 2018).
[cited by examiner]
Melé, Marta, et al. Science 348.6235 (2015): 660-665. (Year: 2015).
[cited by examiner]
Genotype-Tissue Expression database V10, https://gtexportal.org/home/gene/UBE3A (accessed: 2024) (Year: 2024).
[cited by examiner]
Bantel-Schaal et al. “Human Adeno-Associated Virus Type 5 Is Only Distantly Related to Other Known Primate Helper-Dependent Parvoviruses” Journal of Virology, 73(2):939-947 (1999).
[cited by applicant]
Bindels-De Heus et al. “An overview of health issues and development in a large clinical cohort of children with Angelman syndrome” American Journal of Medical Genetics Part A, 182:53-63 (2020).
[cited by applicant]
Chamberlain et al. “Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes” Proceedings of the National Academy of Sciences, 107(41):17668-17673 (2010).
[cited by applicant]
Chao et al. “Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors” Molecular Therapy, 2(6):619-623 (2000).
[cited by applicant]
Chiorini et al. “Cloning and Characterization of Adeno-Associated Virus Type 5” Journal of Virology, 73(2):1309-1319 (1999).
[cited by applicant]
Chiorini et al. “Cloning of Adeno-Associated Virus Type 4 (AAV4) and Generation of Recombinant AAV4 Particles” Journal of Virology, 71(9):6823-6833 (1997).
[cited by applicant]
Conway et al. “High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap” Gene Therapy, 6:986-993 (1999).
[cited by applicant]
Copping et al. “Neuronal overexpression of Ube3a isoform 2 causes behavioral impairments and neuroanatomical pathology relevant to 15q11.2-q13.3 duplication syndrome” Human Molecular Genetics, 26(20):3995-4010 (2017).
[cited by applicant]
Ferrari et al. “New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors” Nature Medicine, 3:1295-1297 (1997).
[cited by applicant]
Fink et al. “Disrupted neuronal maturation in Angelman syndrome-derived induced pluripotent stem cells” Nature Communications, 8:15038 (2017).
[cited by applicant]
Gao et al. “Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues” Journal of Virology, 78(12):6381-6388 (2004).
[cited by applicant]
Gao et al. “Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy” Proceedings of the National Academy of Sciences USA, 99(18):11854-11859 (2002).
[cited by applicant]
GenBank Accession No. AF028704 “Adeno-associated virus 6, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Jan. 12, 1998).
[cited by applicant]
GenBank Accession No. AF028705 “Adeno-associated virus 3B, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Jan. 12, 1998).
[cited by applicant]
GenBank Accession No. AF043303 “Adeno-associated virus 2, complete genome” www.ncbi.nlm.nih.gov (4 pages) (May 20, 2010).
[cited by applicant]
GenBank Accession No. AF063497 “Adeno-associated virus 1, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Apr. 27, 1999).
[cited by applicant]
GenBank Accession No. AF288061 “Hamster parvovirus 5′ terminal hairpin gene sequence” www.ncbi.nlm.nih.gov (1 page) (Apr. 13, 2001).
[cited by applicant]
GenBank Accession No. AF513851 “Adeno-associated virus 7 nonstructural protein and capsid protein genes, complete cds” www.ncbi.nlm.nih.gov (3 pages) (Sep. 5, 2002).
[cited by applicant]
GenBank Accession No. AF513852 “Adeno-associated virus 8 nonstructural protein and capsid protein genes, complete cds” www.ncbi.nlm.nih.gov (3 pages) (Sep. 5, 2002).
[cited by applicant]
GenBank Accession No. AH009962 “Hamster parvovirus” www.ncbi.nlm.nih.gov (2 pages) (Aug. 25, 2016).
[cited by applicant]
GenBank Accession No. AX753250 “Sequence 5 from Patent EP1310571” www.ncbi.nlm.nih.gov (2 pages) (Jun. 23, 2003).
[cited by applicant]
GenBank Accession No. AY028223 “B19 virus isolate patient_A.1.1 genomic sequence” www.ncbi.nlm.nih.gov (1 page) (Apr. 16, 2001).
[cited by applicant]
GenBank Accession No. AY028226 “B19 virus isolate patient_A.2.1 genomic sequence” www.ncbi.nlm.nih.gov (1 page) (Apr. 16, 2001).
[cited by applicant]
GenBank Accession No. AY530579 “Adeno-associated virus 9 isolate hu. 14 capsid protein VP1 (cap) gene, complete cds” www.ncbi.nlm.nih.gov (2 pages) (Jun. 24, 2004).
[cited by applicant]
GenBank Accession No. AY631966 “Adeno-associated virus 11 nonstructural protein and capsid protein genes, complete cds” www.ncbi.nlm.nih.gov (3 pages) (Nov. 30, 2004).
[cited by applicant]
GenBank Accession No. EU285562 “Adeno-associated virus 13 nonstructural protein and capsid protein genes, complete cds” www.ncbi.nlm.nih.gov (3 pages) (Sep. 23, 2008).
[cited by applicant]
GenBank Accession No. J01901 “Adeno-associated virus 2, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Apr. 27, 1993).
[cited by applicant]
GenBank Accession No. J02275 “Minute virus of mice, complete genome” www.ncbi.nlm.nih.gov (5 pages) (May 22, 1995).
[cited by applicant]
GenBank Accession No. NC_000883 “Human parvovirus B19, complete genome” www.ncbi.nlm.nih.gov (4 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NC_001358 “Parvovirus H1, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Feb. 10, 2015).
[cited by applicant]
GenBank Accession No. NC_001401 “Adeno-associated virus—2, complete genome” www.ncbi.nlm.nih.gov (6 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NC_001510 “Minute virus of mice, complete genome” www.ncbi.nlm.nih.gov (5 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NC_001540 “Bovine parvovirus, complete genome” www.ncbi.nlm.nih.gov (4 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NC_001701 “Goose parvovirus, complete genome” www.ncbi.nlm.nih.gov (4 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NC_001729 “Adeno-associated virus-3, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NC_001829 “Adeno-associated virus-4, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NC_001862 “Adeno-associated virus 6, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Jan. 12, 2004).
[cited by applicant]
GenBank Accession No. NC_001863 “Adeno-associated virus 3B, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Jan. 12, 2004).
[cited by applicant]
GenBank Accession No. NC_002077 “Adeno-associated virus-1, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NC_006152 “Adeno-associated virus 5, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NC_006261 “Adeno-associated virus-8, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Aug. 13, 2018).
[cited by applicant]
GenBank Accession No. NM_000462.5 “
[cited by applicant]
GenBank Accession No. NM_130838.3 “
[cited by applicant]
GenBank Accession No. NM_130839.4 “
[cited by applicant]
GenBank Accession No. U89790 “Adeno-associated virus 4, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Aug. 21, 1997).
[cited by applicant]
GenBank Accession No. X01457 “Parvovirus h-1, complete genome” www.ncbi.nlm.nih.gov (3 pages) (Apr. 18, 2005).
[cited by applicant]
Goebbels et al. “Genetic targeting of principal neurons in neocortex and hippocampus of NEX-Cre mice” Genesis, 14(12):611-621 (2006).
[cited by applicant]
Gu et al. “Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice” The Journal of Clinical Investigation, 129(1):163-168 (2019).
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2020/034171 (8 pages) (dated Dec. 2, 2021).
[cited by applicant]
Jiang et al. “Mutation of the Angelman Ubiquitin Ligase in Mice Causes Increased Cytoplasmic p53 and Deficits of Contextual Learning and Long-Term Potentiation” Neuron, 21(4):799-811 (1998).
[cited by applicant]
Judson et al. “Allelic Specificity of Ube3a Expression in the Mouse Brain during Postnatal Development” The Journal of Comparative Neurology, 522(8):1874-1896 (2014).
[cited by applicant]
Judson et al. “Decreased Axon Caliber Underlies Loss of Fiber Tract Integrity, Disproportional Reductions in White Matter Volume and Microcephaly in Angelman Syndrome Model Mice” The Journal of Neuroscience, 37(31):7347…
[cited by applicant]
Krishnan et al. “Autism gene Ube3a and seizures impair sociability by repressing VTA Cbln1” Nature, 543(7646):507-512 (2017).
[cited by applicant]
Margolskee, R. F. “Epstein-Barr Virus Based Expression Vectors” Current Topics in Microbiology and Immunology. 158:67-95 (1992).
[cited by applicant]
Mele et al. “The human transcriptome across tissues and individuals” Science, 348(6235):660-665 (2015).
[cited by applicant]
Miao et al. “The Angelman Syndrome Protein Ube3a Is Required for Polarized Dendrite Morphogenesis in Pyramidal Neurons” The Journal of Neuroscience, 33(1):327-333 (2013).
[cited by applicant]
Mori et al. “Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein” Virology, 330:375-383 (2004).
[cited by applicant]
Muramatsu et al. “Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3” Virology, 221(1):208-217 (1996).
[cited by applicant]
Muzyczka, N. “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells” Current Topics in Microbiology and Immunology, 158:97-98 (1992).
[cited by applicant]
Palombo et al. “Site-Specific Integration in Mammalian Cells Mediated by a New Hybrid Baculovirus-Adeno-Associated Virus Vector” Journal of Virology, 72(6):5025-5034 (1998).
[cited by applicant]
Rotaru et al. “Angelman Syndrome: From Mouse Models to Therapy” Neuroscience, 445:172-189 (2020).
[cited by applicant]
Ruffing et al. “Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: Lack of an RGD integrin-binding motif” Journal of General Virology, 75:3385-3392 (1994).
[cited by applicant]
Rutledge et al. “Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2” Journal of Virology, 72(1):309-319 (1998).
[cited by applicant]
Sadhwani et al. “Two Angelman Families with Unusually Advanced Neurodevelopment Carry a Start Codon Variant in the Most Highly Expressed UBE3A Isoform” American Journal of Medical Genetics—Part A, 176(7):1641-1647 (2018…
[cited by applicant]
Schmidt et al. “Molecular Characterization of the Heparin-Dependent Transduction Domain on the Capsid of a Novel Adeno-Associated Virus Isolate, AAV(VR-942)” Journal of Virology, 82(17):8911-8916 (2008).
[cited by applicant]
Shade et al. “Nucleotide Sequence and Genome Organization of Human Parvovirus B19 Isolated from the Serum of a Child during Aplastic Crisis” Journal of Virology, 58(3):921-936 (1986).
[cited by applicant]
Smith et al. “Increased Gene Dosage of Ube3a Results in Autism Traits and Decreased Glutamate Synaptic Transmission in Mice” Science Translational Medicine, 3(103):103ra97 (2011).
[cited by applicant]
Sommer et al. “iPS Cell Generation Using a Single Lentiviral Stem Cell Cassette” Stem Cells, 27:543-549 (2008).
[cited by applicant]
Srivastava et al. “Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome” Journal of Virology, 45(2):555-564 (1983).
[cited by applicant]
Takahashi et al. “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors” Cell, 131:861-872 (2007).
[cited by applicant]
Trezza et al. “Loss of nuclear UBE3A causes electrophysiological and behavioral deficits in mice and is associated with Angelman syndrome” Nature Neuroscience, 22(8):1235-1247 (2019).
[cited by applicant]
Tyle, Praveen “Iontophoretic Devices for Drug Delivery” Pharmaceutical Research, 3(6):318-326 (1986).
[cited by applicant]
Urabe et al. “Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors” Human Gene Therapy, 13:1935-1943 (2002).
[cited by applicant]
Wang et al. “Expanding the Genetic Code” Annual Review of Biophysics and Biomolecular Structure, 35:225-249 (2006).
[cited by applicant]
Xiao et al. “Gene Therapy Vectors Based on Adeno-Associated Virus Type 1” Journal of Virology, 73(5):3994-4003 (1999).
[cited by applicant]
Zhang et al. “Recombinant adenovirus expressing adeno-associated virus cap and rep proteins supports production of hightiter recombinant adeno-associated virus” Gene Therapy, 8:704-712 (2001).
[cited by applicant]
Zolotukhin et al. “Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield” Gene Therapy, 6:973-985 (1999).
[cited by applicant]
GenBank Accession No. AK292514.1 “
[cited by applicant]
GenBank Accession No. BC002582.2 “
[cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority corresponding to International Patent Application No. PCT/US2020/034171 (13 pages) (mailed Oct. 27, 2020).
[cited by applicant]
Lopez et al. “UBE3A: An E3 Ubiquitin Ligase With Genome-Wide Impact in Neurodevelopmental Disease” Frontiers in Molecular Neuroscience, 11(476):1-8 (2019).
[cited by applicant]
Yamamoto et al. “The Human E6-AP Gene (UBE3A) Encodes Three Potential Protein Isoforms Generated by Differential Splicing” Genomics, 41:263-266 (1997).
[cited by applicant]
“Search Report corresponding to Singapore Application No. 11202112470Y dated Sep. 29, 2023”.
[cited by applicant]
“Written Opinion corresponding to Singapore Application No. 11202112470Y dated Oct. 2, 2023”.
[cited by applicant]
“
[cited by applicant]
Extended European Search Report corresponding to European Patent Application No. 20809370.8 (13 pages) (dated Sep. 25, 2023).
[cited by applicant]
Ameline , et al., “Long-term expression of melanopsin and channelrhodopsin causes no gross alterations in the dystrophic dog retina”, Gene Therapy, 24, 2017, 735-741.
[cited by applicant]
Judson , et al., “Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice”, JCI Insight, 6(20), 2021, e144712.
[cited by applicant]
Sapkota , et al., “Cell-type-specific profiling of alternative translation identifies regulated protein isoform variation in the mouse brain”, Cell Reports, 26, 2019, 594-607.
[cited by applicant]